WO1999042137A3 - Stress promoter control of therapeutic genes in gene therapy: compositions and methods - Google Patents

Stress promoter control of therapeutic genes in gene therapy: compositions and methods Download PDF

Info

Publication number
WO1999042137A3
WO1999042137A3 PCT/IB1999/000294 IB9900294W WO9942137A3 WO 1999042137 A3 WO1999042137 A3 WO 1999042137A3 IB 9900294 W IB9900294 W IB 9900294W WO 9942137 A3 WO9942137 A3 WO 9942137A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
gene therapy
therapeutic genes
promoter control
Prior art date
Application number
PCT/IB1999/000294
Other languages
French (fr)
Other versions
WO1999042137A2 (en
Inventor
Peter Bromley
Original Assignee
Peter Bromley
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peter Bromley filed Critical Peter Bromley
Priority to EP99902755A priority Critical patent/EP1119618A2/en
Priority to AU22948/99A priority patent/AU2294899A/en
Priority to JP2000532150A priority patent/JP2002503709A/en
Publication of WO1999042137A2 publication Critical patent/WO1999042137A2/en
Publication of WO1999042137A3 publication Critical patent/WO1999042137A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1758—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Surgery (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to methods and compositions for the treatment of diseases by gene therapy. More particularly, it relates to the control of therapeutic gene expression by heat shock or stress promoters, the use of mixtures of genes for specific treatments, and the use of optimal induction protocols and systems.
PCT/IB1999/000294 1998-02-19 1999-02-18 Stress promoter control of therapeutic genes in gene therapy: compositions and methods WO1999042137A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP99902755A EP1119618A2 (en) 1998-02-19 1999-02-18 Stress promoter control of therapeutic genes in gene therapy: compositions and methods
AU22948/99A AU2294899A (en) 1998-02-19 1999-02-18 Stress promoter control of therapeutic genes in gene therapy: compositions and methods
JP2000532150A JP2002503709A (en) 1998-02-19 1999-02-18 Regulation of therapeutic genes by stress promoters in gene therapy: compositions and methods

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7526798P 1998-02-19 1998-02-19
US60/075,267 1998-02-19

Publications (2)

Publication Number Publication Date
WO1999042137A2 WO1999042137A2 (en) 1999-08-26
WO1999042137A3 true WO1999042137A3 (en) 1999-10-21

Family

ID=22124593

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB1999/000294 WO1999042137A2 (en) 1998-02-19 1999-02-18 Stress promoter control of therapeutic genes in gene therapy: compositions and methods

Country Status (4)

Country Link
EP (1) EP1119618A2 (en)
JP (1) JP2002503709A (en)
AU (1) AU2294899A (en)
WO (1) WO1999042137A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9930616D0 (en) * 1999-12-24 2000-02-16 Mathilda & Terence Kennedy Ins Activation and inhibition of the immune system
CA2349506C (en) 2001-06-14 2009-12-08 Duke University A method for selective expression of therapeutic genes by hyperthermia
CA2606858A1 (en) * 2005-05-03 2006-11-09 Veterinarmedizinische Universitat Wien Permeable capsules
WO2007026617A1 (en) * 2005-08-29 2007-03-08 Asahi Glass Company, Limited Expression vector, transformant having the expression vector introduced therein, and process for production of heterologous protein
WO2009125332A1 (en) * 2008-04-07 2009-10-15 Peter Bromley New and safe procedure for immunization against infectious diseases agents
US20160324989A1 (en) * 2014-01-17 2016-11-10 Wake Forest University Health Sciences Methods for enhancing the delivery of active agents

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995016771A1 (en) * 1993-12-13 1995-06-22 Pharmagenics, Inc. Vectors and vector systems including genes encoding tumor suppressor proteins and producer cells transformed thereby
WO1997016547A1 (en) * 1995-10-31 1997-05-09 The Board Of Regents, The University Of Texas System ADENOVIRUS-ANTISENSE K-ras EXPRESSION VECTORS AND THEIR APPLICATION IN CANCER THERAPY
EP0819758A2 (en) * 1996-07-16 1998-01-21 Archibald James Mixson Cationic vehicle: DNA complexes and their use in gene therapy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995016771A1 (en) * 1993-12-13 1995-06-22 Pharmagenics, Inc. Vectors and vector systems including genes encoding tumor suppressor proteins and producer cells transformed thereby
WO1997016547A1 (en) * 1995-10-31 1997-05-09 The Board Of Regents, The University Of Texas System ADENOVIRUS-ANTISENSE K-ras EXPRESSION VECTORS AND THEIR APPLICATION IN CANCER THERAPY
EP0819758A2 (en) * 1996-07-16 1998-01-21 Archibald James Mixson Cationic vehicle: DNA complexes and their use in gene therapy

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; WALTHER W ET AL: "Cell type specific and inducible promoters for vectors in gene therapy as an approach for cell targeting.", XP002077061 *
FRICKER J: "Heat-inducible promoters for gene therapy [news].", MOLECULAR MEDICINE TODAY, (1997 MAR) 3 (3) 94-5. JOURNAL CODE: CMK. ISSN: 1357-4310., ENGLAND: United Kingdom, XP002077059 *
JOURNAL OF MOLECULAR MEDICINE, (1996 JUL) 74 (7) 379-92. REF: 82 JOURNAL CODE: B8C. ISSN: 0946-2716., GERMANY: Germany, Federal Republic of *
MADIO D P ET AL: "On the feasibility of MRI-guided focused ultrasound for local induction of gene expression.", JOURNAL OF MAGNETIC RESONANCE IMAGING, (1998 JAN-FEB) 8 (1) 101-4., XP002112841 *
PENNINGTON M E ET AL: "Quantitative assessment of heat inducible gene expression.", SIXTH INTERNATIONAL CONFERENCE ON GENE THERAPY OF CANCER, SAN DIEGO, CALIFORNIA, USA, NOVEMBER 20-22, 1997. CANCER GENE THERAPY 4 (6 CONF. SUPPL.). 1997. S25. ISSN: 0929-1903, XP002077057 *
REYNOLDS ET AL: "MCL-1, A MEMBER OF THE BCL-2 FAMILY, DELAYS APOPTOSIS INDUCED BY C-MYC OVEREXPRESSION IN CHINESE HAMSTER OVARY CELLS", CANCER RESEARCH, vol. 54, 1994, pages 6348 - 6352, XP002076644 *
SUZUKI ET AL: "The Human GATA-6 Gene: Structure, Chromosomal Location, and Regulation of Expression by Tissue-Specific and Mitogen - Responsive Signals", GENOMICS, vol. 38, 1996, pages 283 - 290, XP002077060 *
TANAKA ET AL: "DOWNREGULATION OF FAS LIGAND BY SHEDDING", NATURE MEDICINE, vol. 4, no. 1, January 1998 (1998-01-01), pages 31 - 36, XP002112842 *
TSANG T C ET AL: "New vectors for augmented levels of heat inducible gene expression.", SIXTH INTERNATIONAL CONFERENCE ON GENE THERAPY OF CANCER, SAN DIEGO, CALIFORNIA, USA, NOVEMBER 20-22, 1997. CANCER GENE THERAPY 4 (6 CONF. SUPPL.). 1997. S25. ISSN: 0929-1903, XP002077058 *
VASANWALA F H ET AL: "A novel gene expression vector induced by heat shock, chemotherapy and radiation.", SIXTH INTERNATIONAL CONFERENCE ON GENE THERAPY OF CANCER, SAN DIEGO, CALIFORNIA, USA, NOVEMBER 20-22, 1997. CANCER GENE THERAPY 4 (6 CONF. SUPPL.). 1997. S28. ISSN: 0929-1903, XP002077056 *
WHITE ET AL: "CELL KILLING BY THE DROSOPHILA GENE REAPER", SCIENCE, vol. 271, 1996, pages 805 - 807, XP002076643 *

Also Published As

Publication number Publication date
AU2294899A (en) 1999-09-06
JP2002503709A (en) 2002-02-05
WO1999042137A2 (en) 1999-08-26
EP1119618A2 (en) 2001-08-01

Similar Documents

Publication Publication Date Title
WO2003011887A3 (en) Antisense modulation of apolipoprotein b expression
WO2004054512A3 (en) Therapeutic retroviral vectors for gene therapy
WO2004044181A3 (en) Antisense modulation of apolipoprotein b expression
WO2003014307A3 (en) Antisense modulation of apolipoprotein(a) expression
WO2003097662A8 (en) Antisense modulation of apolipoprotein b expression
WO2003008543A3 (en) Antisense modulation of bcl2-associated x protein expression
AU2002303214A1 (en) Lps-responsive chs1/beige-like anchor gene and therapeutic applications thereof
WO1997022695A3 (en) Nucleotide sequences, proteins, drugs and diagnostic agents for treating cancer
WO2003022222A3 (en) Antisense modulation of protein kinase r expression
WO1999033998A3 (en) Regulatory dna sequences of the human catalytic telomerase sub-unit gene, diagnostic and therapeutic use thereof
WO1998059040A3 (en) Human catalytic telomerase sub-unit and its diagnostic and therapeutic use
WO2003014306A3 (en) Antisense modulation of cholesteryl ester transfer protein expression
WO1999042137A3 (en) Stress promoter control of therapeutic genes in gene therapy: compositions and methods
WO2003053341A3 (en) Antisense modulation of ship-1 expression
WO2002095053A3 (en) Antisense modulation of src-c expression
WO2003012031A3 (en) Antisense modulation of stearoyl-coa desaturase expression
WO2003052062A3 (en) Antisense modulation of cd36l1 expression
WO2004010956A3 (en) Antisense modulation of lar expression
WO2001081404A3 (en) INDUCIBLE PLASMID VECTOR ENCODING TGF-β AND USES THEREOF
WO2003080800A3 (en) Prevention and treatment of disease using angiogenesis-and/or tumor antigens
WO2003102019A3 (en) Antisense modulation of sterol regulatory element-binding protein-1 expression
WO2000043028A3 (en) Method of treating chronic cardiac disease
WO2003040161A3 (en) Antisense modulation of activating transcription factor 3 expression
WO2003016343A3 (en) USE OF αCP1, αCP2, AND HUR FOR MODULATING GENE EXPRESSION AND INDUCING ANGIOGENESIS
WO2004001061A3 (en) Antisense modulation of heme oxygenase 1 expression

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1999902755

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09622482

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1999902755

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999902755

Country of ref document: EP